{"nctId":"NCT02316353","briefTitle":"A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema","startDateStruct":{"date":"2014-12-31","type":"ACTUAL"},"conditions":["Hereditary Angioedema Types I and II"],"count":126,"armGroups":[{"label":"C1-INH - low-volume dose","type":"EXPERIMENTAL","interventionNames":["Biological: C1-esterase inhibitor"]},{"label":"C1-INH - medium-volume dose","type":"EXPERIMENTAL","interventionNames":["Biological: C1-esterase inhibitor"]}],"interventions":[{"name":"C1-esterase inhibitor","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Males or females aged 6 years or older.\n* A confirmed diagnosis of HAE type I or II.\n* HAE attacks over a consecutive 2-month period that required acute treatment, medical attention, or caused significant functional impairment.\n* For subjects who have used oral therapy for prophylaxis against HAE attacks within 3 months of first study visit: use of a stable regimen within 3 months of the first study visit.\n\nExclusion Criteria:\n\n* Incurable malignancies.\n* Any clinical condition that will interfere with the evaluation of C1-INH therapy.\n* Clinically significant history of poor response to C1-esterase therapy for the management of HAE.\n* Suspected or confirmed diagnosis of acquired HAE or HAE with normal C1-INH.\n* Inability to have HAE managed pharmacologically with on-demand treatment.","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Person-time Incidence Rates (Subject Based)","description":"Subject-based Analysis for Person-Time Incidence Rate = (the total number of subjects who experienced the event during the respective treatment) / (the sum of the date each subject experienced the event - the subject's start date + 1 day) / (365.25 days). The analysis population for this endpoint was the Safety Population: the Safety Population comprised all subjects who provided informed consent / assent, who were randomized, and who received at least 1 dose or a partial dose of CSL830.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":null},{"groupId":"OG001","value":"0.03","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null},{"groupId":"OG001","value":"0.01","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null},{"groupId":"OG001","value":"0.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null},{"groupId":"OG001","value":"0.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null},{"groupId":"OG001","value":"0.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null},{"groupId":"OG001","value":"0.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":null},{"groupId":"OG001","value":"0.06","spread":null}]}]}]},{"type":"PRIMARY","title":"The Person-time Incidence Rates (Event Based)","description":"Event-based Analysis for Person-Time Incidence Rate = (the total number of events documented during the respective treatment) / (the sum of each subject's end date - the subject's start date + 1 day) / (365.25 days). The analysis population for this endpoint was the Safety Population: The Safety Population comprised all subjects who provided informed consent / assent, who were randomized, and who received at least 1 dose or a partial dose of CSL830.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":null},{"groupId":"OG001","value":"0.03","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null},{"groupId":"OG001","value":"0.01","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null},{"groupId":"OG001","value":"0.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null},{"groupId":"OG001","value":"0.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null},{"groupId":"OG001","value":"0.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null},{"groupId":"OG001","value":"0.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":null},{"groupId":"OG001","value":"0.09","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Who Have Solicited Adverse Events (AEs)","description":"The number of subjects having at least 1 solicited local AE during a treatment were divided by the number of subjects in the corresponding treatment. The analysis population for this endpoint was the Safety Population: The Safety Population comprised all subjects who provided informed consent / assent, who were randomized, and who received at least 1 dose or a partial dose of CSL830.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.6","spread":null},{"groupId":"OG001","value":"45.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Injections Followed by At Least One Solicited Adverse Event","description":"The percent of injections followed by at least one solicited adverse event. The analysis population for this endpoint was the Safety Population: The Safety Population comprised all subjects who provided informed consent / assent, who were randomized, and who received at least 1 dose or a partial dose of CSL830. This was assessed across all participants, calculated as total number of events following injections / total number of injections across all participants, in each Arm.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":null},{"groupId":"OG001","value":"5.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Who Become Seropositive for Human Immunodeficiency Virus (HIV-1/-2), Hepatitis B Virus, or Hepatitis C Virus.","description":"Blood samples to be tested for HIV-1/-2, HBV, and HCV. The analysis population for this endpoint was the Safety Population: The Safety Population comprised all subjects who provided informed consent / assent, who were randomized, and who received at least 1 dose or a partial dose of CSL830.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Who Experience a Time-normalized HAE Attack Frequency of <1 HAE Attack Per 4-Week Period","description":"The percentage of subjects with a time-normalized merged HAE attack frequency of \\<1 HAE attack per 4-week period. The analysis population for this endpoint was the Intent-to-Treat (ITT) Population: The ITT Population comprised all subjects who provided informed consent / assent and were randomized, regardless of whether or not they received CSL 830.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79.4","spread":null},{"groupId":"OG001","value":"85.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Who Are Responders","description":"A responder was defined as a subject with a â‰¥ 50% reduction in the time-normalized number of HAE attacks on CSL830 relative to the time-normalized number of HAE attacks used to qualify for participation in the current study. The analysis population for this endpoint was the Intent-to-Treat (ITT) Population: The ITT Population comprised all subjects who provided informed consent / assent and were randomized, regardless of whether or not they received CSL830. Not all subjects in the ITT were available for this outcome measure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.5","spread":null},{"groupId":"OG001","value":"91.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":63},"commonTop":["Nasopharyngitis","Injection site pain","Injection site erythema","Headache","Injection site bruising"]}}}